Inventiva Taps Biopharma Veteran Benecchi as COO Ahead of Key MASH Trial Results
Event summary
- Inventiva appoints Chris Benecchi as Chief Operating Officer effective August 31, 2026.
- Benecchi brings 30 years of biopharmaceutical leadership, including COO roles at Sage Therapeutics and Motric Bio.
- Appointment comes ahead of NATiV3 Phase 3 topline results for lanifibranor in MASH, expected Q4 2026.
- Potential U.S. launch of lanifibranor anticipated in 2028, subject to regulatory approval.
- Inventiva is building operational infrastructure for commercialization of MASH treatment.
The big picture
Inventiva's appointment of Benecchi underscores the strategic importance of operational readiness as it approaches pivotal trial results. The move reflects broader industry trends where biopharma companies bolster leadership teams ahead of potential commercial milestones. With MASH emerging as a high-priority therapeutic area, Inventiva's ability to execute on its launch plans will be critical in capturing market share against established and emerging competitors.
What we're watching
- Trial Timing
- Whether NATiV3 Phase 3 results will meet expectations and support regulatory filings.
- Commercial Readiness
- The pace at which Inventiva can establish operational capabilities for a 2028 launch.
- Market Positioning
- How Inventiva will differentiate lanifibranor in the competitive MASH treatment landscape.